After announcing plans to go public at the top of the year, Eikon Therapeutics has now revealed the proceeds it hopes to pull in from its initial stock offering: $273.5 million. The oncology biotech ...

Eikon Therapeutics is heading to the Nasdaq this morning with an upsized $381 million IPO in a further sign of the renewed appeal of the public markets. The oncology biotech will offer 21.2 million ...

Eikon Therapeutics has raised $381 million from its IPO, at the top end of its expectations, in another sign of a pickup in appetite for new biotech listings on the Nasdaq. The South San Francisco ...

Despite progress made in cancer immunotherapy, some patients don’t respond to these treatments or they stop responding after a period of time. Eikon Therapeutics’ lead drug candidate could address ...

MILLBRAE, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing important, innovative medicines to ...

Microsoft has announced that the Microsoft Agent Framework has reached Release Candidate status for both .NET and Python. This milestone indicates that the API surface is stable and feature-complete ...

Former MSD head of R&D Roger Perlmutter has continued the swift development track for cancer start-up Eikon Therapeutics, filing an IPO to build its already healthy cash position further. Eikon has ...

Feb 5 (Reuters) - Drug developer Eikon Therapeutics , headed by Merck veteran Roger Perlmutter, was valued at about $860.3 million after its shares opened 5.3% below their offer price in their Nasdaq ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Eikon Therapeutics increased the ...

Eikon Therapeutics raised an upsized US$381m late Wednesday from its Nasdaq IPO that included participation by Merck, a banker involved in the offering told IFR. The banks were multiple times ...

Eikon ‍Therapeutics (EIKN), a cancer drug developer led by Merck (MRK) veteran Roger Perlmutter, has filed for its U.S. IPO seeking a valuation of up to $908M with roughly 17.6M shares on offer. The ...

Oncology-focused Eikon Therapeutics Inc. set the terms of its IPO Jan. 28, selling 17.648 million shares at a price range between $16 to $18 per share. At the top of the range, the Millbrae, ...